Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.

V. K. Panthi, S. K. Jha, R. Pangeni, and K. R. Paudel, “Formulation and Development of Adapalene Topical Nanohydrogel Using Different Surfactants and Cosurfactants for Antiacne Activity: In Vitro and Ex Vivo Evaluation,” J. Nanomater. vol. 2022;2022, https://doi.org/10.1155/2022/6889293 .

P. Kesharwani, K. Jain, and N. K. Jain, “Dendrimer as nanocarrier for drug delivery,” 2014. https://doi.org/10.1016/j.progpolymsci.2013.07.005 .

P. Kesharwani and A. K. Iyer, “Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery,” May 01, 2015, Elsevier Ltd. https://doi.org/10.1016/j.drudis.2014.12.012 .

P. Kesharwani et al., “PAMAM dendrimers as promising nanocarriers for RNAi therapeutics,” 2015, Elsevier. https://doi.org/10.1016/j.mattod.2015.06.003 .

Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: A comparison. Nanomedicine Nanotechnol Biol Med. 2011;7(3):295–304. https://doi.org/10.1016/j.nano.2010.10.010 .

doi: 10.1016/j.nano.2010.10.010

Kim SA, et al. Oral Cancer Immunotherapy through a Simvastatin-Loaded Colloidal Dispersion System for the Generation of Sustained Antitumor Immunity. Adv Ther. 2021;4(8):2100025. https://doi.org/10.1002/ADTP.202100025 .

doi: 10.1002/ADTP.202100025

P. Kesharwani, R. K. Tekade, and N. K. Jain, “Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations,” Pharm. Res., vol. 32, no. 4, 2015, https://doi.org/10.1007/s11095-014-1549-2 .

P. Kesharwani, H. Choudhury, J. G. Meher, M. Pandey, and B. Gorain, “Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging,” Jun. 01, 2019, Elsevier Ltd. https://doi.org/10.1016/j.pmatsci.2019.03.003 .

V. Mishra and P. Kesharwani, “Dendrimer technologies for brain tumor,” Drug Discov. Today, vol. 21, no. 5, 2016, https://doi.org/10.1016/j.drudis.2016.02.006 .

Singh V, Kesharwani P. Recent advances in microneedles-based drug delivery device in the diagnosis and treatment of cancer. J Controlled Release. 2021;338:394–409. https://doi.org/10.1016/J.JCONREL.2021.08.054 .

doi: 10.1016/J.JCONREL.2021.08.054

J. U. Choi et al., “Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion,” J Control Release Off J Control. Release Soc., vol. 322, pp. 13–30, Jun. 2020, https://doi.org/10.1016/J.JCONREL.2020.03.012 .

M. Imran et al., “Overcoming Multidrug Resistance of Antibiotics via Nanodelivery Systems,” Pharm. 2022 Vol 14 Page 586, vol. 14, no. 3, p. 586, Mar. 2022, https://doi.org/10.3390/PHARMACEUTICS14030586 .

Kesharwani P, Gothwal A, Iyer AK, Jain K, Chourasia MK, Gupta U. Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery. Drug Discov Today. 2018;23(2):300–14. https://doi.org/10.1016/j.drudis.2017.06.009 .

doi: 10.1016/j.drudis.2017.06.009 pubmed: 28697371

Surekha B, Kommana NS, Dubey SK, Kumar AVP, Shukla R, Kesharwani P. PAMAM dendrimer as a talented multifunctional biomimetic nanocarrier for cancer diagnosis and therapy. Colloids Surf B Biointerfaces. 2021;204:111837. https://doi.org/10.1016/j.colsurfb.2021.111837 .

doi: 10.1016/j.colsurfb.2021.111837 pubmed: 33992888

Singh V, Sahebkar A, Kesharwani P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery. Eur Polym J. 2021;158:110683. https://doi.org/10.1016/J.EURPOLYMJ.2021.110683 .

doi: 10.1016/J.EURPOLYMJ.2021.110683

Kesharwani P, Tekade RK, Jain NK. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomed. 2014;9(15):2291–308.

doi: 10.2217/nnm.13.210

Kesharwani P, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. Curr Drug Targets. 2011;12(10):1478–97.

doi: 10.2174/138945011796818135 pubmed: 21443471

Pangeni R, et al. Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer. Int J Nanomedicine. 2020;15:7719–43. https://doi.org/10.2147/IJN.S267424 .

doi: 10.2147/IJN.S267424 pubmed: 33116497 pmcid: 7555381

R. Pangeni, S. Kang, S. K. Jha, L. Subedi, and J. W. Park, “Intestinal membrane transporter-mediated approaches to improve oral drug delivery,” J Pharm Investig. 2021 512, vol. 51, no. 2, pp. 137–158, Feb. 2021, https://doi.org/10.1007/S40005-021-00515-1 .

Jee JP, Pangeni R, Jha SK, Byun Y, Park JW. Preparation and in vivo evaluation of a topical hydrogel system incorporating highly skin-permeable growth factors, quercetin, and oxygen carriers for enhanced diabetic wound-healing therapy. Int J Nanomedicine. 2019;14:5449–75. https://doi.org/10.2147/IJN.S213883 .

doi: 10.2147/IJN.S213883 pubmed: 31409998 pmcid: 6647010

P. Kesharwani, V. Mishra, and N. K. Jain, “Validating the anticancer potential of carbon nanotube-based therapeutics through cell line testing,” Drug Discov. Today, vol. 20, no. 9, 2015, https://doi.org/10.1016/j.drudis.2015.05.004 .

P. Kesharwani et al., “Gold nanoparticles and gold nanorods in the landscape of cancer therapy,” Mol. Cancer. 2023 221, vol. 22, no. 1, pp. 1–31, Jun. 2023, https://doi.org/10.1186/S12943-023-01798-8 .

Y. Yao et al., “Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance,” Aug. 2020, Frontiers Media S.A. https://doi.org/10.3389/fmolb.2020.00193 .

L. A. Jha, B. Kumar, S. K. Jha, and K. R. Paudel, “Futuristic senolytic drug incorporated nanomedicine therapy to treat osteoarthritis,” Nanomed., vol. 19, no. 10, Apr. 2024, https://doi.org/10.2217/NNM-2023-0348 .

Imran M, et al. ‘Nanodecoys’ - Future of drug delivery by encapsulating nanoparticles in natural cell membranes. Int J Pharm. 2022;621:121790. https://doi.org/10.1016/J.IJPHARM.2022.121790 .

doi: 10.1016/J.IJPHARM.2022.121790 pubmed: 35504432

Jha SK, et al. A Comprehensive review on Pharmacokinetic Studies of Vaccines: Impact of delivery route, carrier-and its modulation on immune response. Environ Res. 2023;236:116823. https://doi.org/10.1016/J.ENVRES.2023.116823 .

doi: 10.1016/J.ENVRES.2023.116823 pubmed: 37543130

Hasan N, et al. Advanced targeted drug delivery by bioengineered white blood cell-membrane camouflaged nanoparticulate delivery nanostructures. Environ Res. 2023;238:117007. https://doi.org/10.1016/J.ENVRES.2023.117007 .

doi: 10.1016/J.ENVRES.2023.117007 pubmed: 37689337

S. K. Jha et al., “Cellular Senescence in Lung Cancer: Molecular Mechanisms and Therapeutic Interventions,” Ageing Res. Rev., p. 102315, Apr. 2024, https://doi.org/10.1016/J.ARR.2024.102315 .

Mukherjee S, Mukherjee S, Abourehab MAS, Sahebkar A, Kesharwani P. Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. Eur Polym J. 2022;177:111471. https://doi.org/10.1016/J.EURPOLYMJ.2022.111471 .

doi: 10.1016/J.EURPOLYMJ.2022.111471

Sheikh A, Md S, Kesharwani P. Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomed Pharmacother. 2022;146:112530. https://doi.org/10.1016/J.BIOPHA.2021.112530 .

doi: 10.1016/J.BIOPHA.2021.112530 pubmed: 34915416

Singh R, Shitiz K, Singh A. Chitin and chitosan: biopolymers for wound management. Int Wound J. 2017;14(6):1276–89. https://doi.org/10.1111/IWJ.12797 .

doi: 10.1111/IWJ.12797 pubmed: 28799228 pmcid: 7949833

Sheikh A, Md S, Alhakamy NA, Kesharwani P. Recent development of aptamer conjugated chitosan nanoparticles as cancer therapeutics. Int J Pharm. 2022;620:121751. https://doi.org/10.1016/J.IJPHARM.2022.121751 .

doi: 10.1016/J.IJPHARM.2022.121751 pubmed: 35436511

V. S. Madamsetty et al., “Chitosan: A versatile bio-platform for breast cancer theranostics,” J Control Release Off J Control Release Soc., vol. 341, pp. 733–752, Jan. 2021, https://doi.org/10.1016/J.JCONREL.2021.12.012 .

Rathore P, Mahor A, Jain S, Haque A, Kesharwani P. Formulation development,: In vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin. RSC Adv. 2020;10(71):43629–39. https://doi.org/10.1039/d0ra07640f .

doi: 10.1039/d0ra07640f pubmed: 35519724 pmcid: 9058365

Dongsar TT, Dongsar TS, Gupta N, Almalki WH, Sahebkar A, Kesharwani P. Emerging potential of 5-Fluorouracil-loaded chitosan nanoparticles in cancer therapy. J Drug Deliv Sci Technol. 2023;82:104371. https://doi.org/10.1016/J.JDDST.2023.104371 .

doi: 10.1016/J.JDDST.2023.104371

P. Kesharwani et al., “Itraconazole and Difluorinated-Curcumin Containing Chitosan Nanoparticle Loaded Hydrogel for Amelioration of Onychomycosis,” Biomim. 2022 Vol 7 Page 206, vol. 7, no. 4, p. 206, Nov. 2022, https://doi.org/10.3390/BIOMIMETICS7040206 .

Sheikh A, et al. Hyaluronic acid engineered gallic acid embedded chitosan nanoparticle as an effective delivery system for treatment of psoriasis. Environ Res. 2023;238:117086. https://doi.org/10.1016/J.ENVRES.2023.117086 .

doi: 10.1016/J.ENVRES.2023.117086 pubmed: 37683783

Rodrigues S, Dionísio M, López CR, Grenha A. Biocompatibility of Chitosan Carriers with Application in Drug Delivery. J Funct Biomater. 2012;3(3):615–41. https://doi.org/10.3390/jfb3030615 .

doi: 10.3390/jfb3030615 pubmed: 24955636 pmcid: 4030999

N. Desai et al., “Chitosan: A Potential Biopolymer in Drug Delivery and Biomedical Applications,” Pharm. 2023 Vol 15 Page 1313, vol. 15, no. 4, p. 1313, Apr. 2023, https://doi.org/10.3390/PHARMACEUTICS15041313 .

Xu J, et al. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Acta Biomater. 2017;48:247–57. https://doi.org/10.1016/J.ACTBIO.2016.10.026 .

doi: 10.1016/J.ACTBIO.2016.10.026 pubmed: 27769943

Pavoni JMF, Luchese CL, Tessaro IC. Impact of acid type for chitosan dissolution on the characteristics and biodegradability of cornstarch/chitosan based films. Int J Biol Macromol. 2019;138:693–703. https://doi.org/10.1016/J.IJBIOMAC.2019.07.089 .

doi: 10.1016/J.IJBIOMAC.2019.07.089 pubmed: 31306704

C. P. Jiménez-Gómez, J. A. Cecilia, M. Guidotti, and R. Soengas, “Chitosan: A Natural Biopolymer with a Wide and Varied Range of Applications,” Mol. 2020 Vol 25 Page 3981, vol. 25, no. 17, p. 3981, Sep. 2020, https://doi.org/10.3390/MOLECULES25173981 .

Prabaharan M, Mano JF. Chitosan-Based Particles as Controlled Drug Delivery Systems. Drug Deliv. 2004;12(1):41–57. https://doi.org/10.1080/10717540590889781 .

doi: 10.1080/10717540590889781

Hong F, et al. Chitosan-based hydrogels: From preparation to applications, a review. Food Chem X. 2024;21: 101095. https://doi.org/10.1016/J.FOCHX.2023.101095 .

doi: 10.1016/J.FOCHX.2023.101095 pubmed: 38268840

Liu H, et al. A functional chitosan-based hydrogel as a wound dressing and drug delivery system in the treatment of wound healing. RSC Adv. 2018;8(14):7533–49. https://doi.org/10.1039/C7RA13510F .

doi: 10.1039/C7RA13510F pubmed: 35539132 pmcid: 9078458

D. Yan, Y. Li, Y. Liu, N. Li, X. Zhang, and C. Yan, “Antimicrobial Properties of Chitosan and Chitosan Derivatives in the Treatment of Enteric Infections,” Mol. 2021 Vol 26 Page 7136, vol. 26, no. 23, p. 7136, Nov. 2021, https://doi.org/10.3390/MOLECULES26237136 .

Fernández M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci. 2018;9(4):790–810. https://doi.org/10.1039/C7SC04004K .

doi: 10.1039/C7SC04004K pubmed: 29675145

L. E. Kelemen, “The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander?,” Jul. 15, 2006. https://doi.org/10.1002/ijc.21712 .

J. Quevedo-Ocampo et al., “Folate Metabolism in Hepatocellular Carcinoma. What Do We Know So Far?,” Technol. Cancer Res. Treat., vol. 21, Jan. 2022, https://doi.org/10.1177/15330338221144446 .

Frigerio B, et al. Folate receptors and transporters: Biological role and diagnostic/therapeutic targets in cancer and other diseases. J Exp Clin Cancer Res. 2019;38(1):1–12. https://doi.org/10.1186/S13046-019-1123-1/FIGURES/2 .

doi: 10.1186/S13046-019-1123-1/FIGURES/2

Young O, et al. Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. Curr Probl Cancer. 2023;47(1):100917. https://doi.org/10.1016/J.CURRPROBLCANCER.2022.100917 .

doi: 10.1016/J.CURRPROBLCANCER.2022.100917 pubmed: 36508886

Kalli KR, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619–26. https://doi.org/10.1016/J.YGYNO.2007.11.020 .

doi: 10.1016/J.YGYNO.2007.11.020 pubmed: 18222534 pmcid: 2707764

Feng Y, et al. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res Ther. 2011;13(2):1–12. https://doi.org/10.1186/AR3312/FIGURES/7 .

doi: 10.1186/AR3312/FIGURES/7

Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3(1):18496. https://doi.org/10.3402/NANO.V3I0.18496 .

doi: 10.3402/NANO.V3I0.18496

Elieh-Ali-Komi D, Hamblin MR. Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. Int J Adv Res. 2016;4(3):411–27.

Alemu D, Getachew E, Mondal AK. Study on the Physicochemical Properties of Chitosan and their Applications in the Biomedical Sector. Int J Polym Sci. 2023;2023(1):5025341. https://doi.org/10.1155/2023/5025341 .

doi: 10.1155/2023/5025341

Mohite P, et al. Chitosan and chito-oligosaccharide: a versatile biopolymer with endless grafting possibilities for multifarious applications. Front Bioeng Biotechnol. 2023;11:1190879. https://doi.org/10.3389/fbioe.2023.1190879 .

doi: 10.3389/fbioe.2023.1190879 pubmed: 37274159 pmcid: 10235636

Jiang Y, Fu C, Wu S, Liu G, Guo J, Su Z. Determination of the Deacetylation Degree of Chitooligosaccharides. Mar Drugs. 2017;15(11):332. https://doi.org/10.3390/md15110332 .

doi: 10.3390/md15110332 pubmed: 29068401 pmcid: 5706022

Yadav M, Kaushik B, Rao GK, Srivastava CM, Vaya D. Advances and challenges in the use of chitosan and its derivatives in biomedical fields: A review. Carbohydr Polym Technol Appl. 2023;5:100323. https://doi.org/10.1016/j.carpta.2023.100323 .

doi: 10.1016/j.carpta.2023.100323

Aguanell A, et al. Chitosan sulfate-lysozyme hybrid hydrogels as platforms with fine-tuned degradability and sustained inherent antibiotic and antioxidant activities. Carbohydr Polym. 2022;291:119611. https://doi.org/10.1016/j.carbpol.2022.119611 .

doi: 10.1016/j.carbpol.2022.119611 pubmed: 35698348

Amor IB, Hemmami H, Laouini SE, Abdelaziz AG, Barhoum A. Influence of chitosan source and degree of deacetylation on antibacterial activity and adsorption of AZO dye from water. Biomass Convers Biorefinery. 2024;14(14):16245–55. https://doi.org/10.1007/s13399-023-03741-9 .

doi: 10.1007/s13399-023-03741-9

Wang QZ, et al. Protonation constants of chitosan with different molecular weight and degree of deacetylation. Carbohydr Polym. 2006;65(2):194–201. https://doi.org/10.1016/j.carbpol.2006.01.001 .

doi: 10.1016/j.carbpol.2006.01.001

Mourya VK, Inamdar NN. Chitosan-modifications and applications: Opportunities galore. React Funct Polym. 2008;68(6):1013–51. https://doi.org/10.1016/j.reactfunctpolym.2008.03.002 .

doi: 10.1016/j.reactfunctpolym.2008.03.002

Sacco P, Pedroso-Santana S, Kumar Y, Joly N, Martin P, Bocchetta P. Ionotropic Gelation of Chitosan Flat Structures and Potential Applications. Molecules. 2021;26(3):660. https://doi.org/10.3390/molecules26030660 .

doi: 10.3390/molecules26030660 pubmed: 33513925 pmcid: 7865838

Yanat M, Schroën K. Preparation methods and applications of chitosan nanoparticles; with an outlook toward reinforcement of biodegradable packaging. React Funct Polym. 2021;161:104849. https://doi.org/10.1016/j.reactfunctpolym.2021.104849 .

doi: 10.1016/j.reactfunctpolym.2021.104849

Kumar S, Dilbaghi N, Saharan R, Bhanjana G. Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs. BioNanoScience. 2012;2(4):227–50. https://doi.org/10.1007/s12668-012-0060-7 .

doi: 10.1007/s12668-012-0060-7

Napiórkowska A, Kurek M. Coacervation as a Novel Method of Microencapsulation of Essential Oils—A Review. Molecules. 2022;27(16):5142. https://doi.org/10.3390/molecules27165142 .

doi: 10.3390/molecules27165142 pubmed: 36014386 pmcid: 9416238

S. Milenkova, R. Ambrus, M. Mukhtar, B. Pilicheva, and M. Marudova, “Spray-Dried Chitosan Hydrogel Particles as a Potential Delivery System for Benzydamine Hydrochloride,” Gels, vol. 10, no. 3, Art. no. 3, Mar. 2024, https://doi.org/10.3390/gels10030189 .

Castillo-Henríquez L, Vargas-Zúñiga R, Pacheco-Molina J, Vega-Baudrit J. Electrospun nanofibers: A nanotechnological approach for drug delivery and dissolution optimization in poorly water-soluble drugs. ADMET DMPK. 2020;8(4):325–53. https://doi.org/10.5599/admet.844 .

doi: 10.5599/admet.844 pubmed: 35300196 pmcid: 8915594

Kantak MN, Bharate SS. Analysis of clinical trials on biomaterial and therapeutic applications of chitosan: A review. Carbohydr Polym. 2022;278:118999. https://doi.org/10.1016/j.carbpol.2021.118999 .

doi: 10.1016/j.carbpol.2021.118999 pubmed: 34973801

Herdiana Y, Wathoni N, Shamsuddin S, Joni IM, Muchtaridi M. Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment. Polymers. 2021;13(11):1717. https://doi.org/10.3390/polym13111717 .

doi: 10.3390/polym13111717 pubmed: 34074020 pmcid: 8197416

Qindeel M, Ahmed N, Khan GM, Rehman AU. Ligand decorated chitosan as an advanced nanocarrier for targeted delivery: a critical review. Nanomed. 2019;14(12):1623–42. https://doi.org/10.2217/nnm-2018-0490 .

doi: 10.2217/nnm-2018-0490

Alinejad V, et al. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. Biomed Pharmacother. 2016;83:229–40. https://doi.org/10.1016/j.biopha.2016.06.037 .

doi: 10.1016/j.biopha.2016.06.037 pubmed: 27372407

Sun I-C, Ahn C-H, Kim K, Emelianov S. Photoacoustic imaging of cancer cells with glycol-chitosan-coated gold nanoparticles as contrast agents. J Biomed Opt. 2019;24(12):1–5. https://doi.org/10.1117/1.JBO.24.12.121903 .

doi: 10.1117/1.JBO.24.12.121903 pubmed: 31385483

A. Kumar Mehata et al., “Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy,” Colloids Surf. B Biointerfaces, vol. 173, pp. 366–377, Jan. 2019, https://doi.org/10.1016/j.colsurfb.2018.10.007 .

Wang Y, et al. Sequentially self-assembled polysaccharide-based nanocomplexes for combined chemotherapy and photodynamic therapy of breast cancer. Carbohydr Polym. 2019;203:203–13. https://doi.org/10.1016/j.carbpol.2018.09.035 .

doi: 10.1016/j.carbpol.2018.09.035 pubmed: 30318205

D. Pertiwi, R. Martien, - Sismindari, and H. Ismail, “Formulation of nanoparticles ribosome inactivating proteins from Mirabilis jalapa L. (RIP MJ) conjugated AntiEpCAM antibody using low chain chitosan-pectin and cytotoxic activity against breast cancer cell line,” Pak. J. Pharm. Sci., vol. 31, no. 2, pp. 379–384, Mar. 2018.

Kievit FM, et al. Targeting of Primary Breast Cancers and Metastases in a Transgenic Mouse Model Using Rationally Designed Multifunctional SPIONs. ACS Nano. 2012;6(3):2591–601. https://doi.org/10.1021/nn205070h .

doi: 10.1021/nn205070h pubmed: 22324543 pmcid: 3397248

Luesakul U, Komenek S, Puthong S, Muangsin N. Shape-controlled synthesis of cubic-like selenium nanoparticles via the self-assembly method. Carbohydr Polym. 2016;153:435–44. https://doi.org/10.1016/j.carbpol.2016.08.004 .

doi: 10.1016/j.carbpol.2016.08.004 pubmed: 27561515

Niu S, et al. A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy. J Nanobiotechnology. 2019;17(1):95. https://doi.org/10.1186/s12951-019-0529-4 .

doi: 10.1186/s12951-019-0529-4 pubmed: 31506085 pmcid: 6737697

Hou G, et al. A novel pH-sensitive targeting polysaccharide-gold nanorod conjugate for combined photothermal-chemotherapy of breast cancer. Carbohydr Polym. 2019;212:334–44. https://doi.org/10.1016/j.carbpol.2019.02.045 .

doi: 10.1016/j.carbpol.2019.02.045 pubmed: 30832865

M. Danaei et al., “Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems,” Pharmaceutics, vol. 10, no. 2, Art. no. 2, Jun. 2018, https://doi.org/10.3390/pharmaceutics10020057 .

Mathew ME, Mohan JC, Manzoor K, Nair SV, Tamura H, Jayakumar R. Folate conjugated carboxymethyl chitosan–manganese doped zinc sulphide nanoparticles for targeted drug delivery and imaging of cancer cells. Carbohydr Polym. 2010;2(80):442–8. https://doi.org/10.1016/j.carbpol.2009.11.047 .

doi: 10.1016/j.carbpol.2009.11.047

Jiang H, Wu H, Xu Y, Wang J, Zeng Y. Preparation of galactosylated chitosan/tripolyphosphate nanoparticles and application as a gene carrier for targeting SMMC7721 cells. J Biosci Bioeng. 2011;111(6):719–24. https://doi.org/10.1016/j.jbiosc.2011.01.012 .

doi: 10.1016/j.jbiosc.2011.01.012 pubmed: 21334972

Gu J, Al-Bayati K, Ho EA. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Deliv Transl Res. 2017;7(4):497–506. https://doi.org/10.1007/s13346-017-0368-5 .

doi: 10.1007/s13346-017-0368-5 pubmed: 28315051

Lee J, et al. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug Chem. 2012;23(6):1174–80. https://doi.org/10.1021/bc2006219 .

doi: 10.1021/bc2006219 pubmed: 22607555

Kim TH, Jin H, Kim HW, Cho M-H, Cho CS. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther. 2006;5(7):1723–32. https://doi.org/10.1158/1535-7163.MCT-05-0540 .

doi: 10.1158/1535-7163.MCT-05-0540 pubmed: 16891458

Zhu XL, et al. Galactosylated Chitosan Oligosaccharide Nanoparticles for Hepatocellular Carcinoma Cell-Targeted Delivery of Adenosine Triphosphate. Int J Mol Sci. 2013;14(8):15755–66. https://doi.org/10.3390/ijms140815755 .

doi: 10.3390/ijms140815755 pubmed: 23899789 pmcid: 3759884

Zhou N, et al. Galactosylated chitosan-polycaprolactone nanoparticles for hepatocyte-targeted delivery of curcumin. Carbohydr Polym. 2013;94(1):420–9. https://doi.org/10.1016/j.carbpol.2013.01.014 .

doi: 10.1016/j.carbpol.2013.01.014 pubmed: 23544558

Cheng M-R, et al. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol WJG. 2012;18(42):6076–87. https://doi.org/10.3748/wjg.v18.i42.6076 .

doi: 10.3748/wjg.v18.i42.6076 pubmed: 23155336

Jhaveri J, Raichura Z, Khan T, Momin M, Omri A. Chitosan Nanoparticles-Insight into Properties, Functionalization and Applications in Drug Delivery and Theranostics. Mol Basel Switz. 2021;26(2):272. https://doi.org/10.3390/molecules26020272 .

doi: 10.3390/molecules26020272

Kashyap PL, Xiang X, Heiden P. Chitosan nanoparticle based delivery systems for sustainable agriculture. Int J Biol Macromol. 2015;77:36–51. https://doi.org/10.1016/j.ijbiomac.2015.02.039 .

doi: 10.1016/j.ijbiomac.2015.02.039 pubmed: 25748851

Koukaras EN, Papadimitriou SA, Bikiaris DN, Froudakis GE. Insight on the formation of chitosan nanoparticles through ionotropic gelation with tripolyphosphate. Mol Pharm. 2012;9(10):2856–62. https://doi.org/10.1021/mp300162j .

doi: 10.1021/mp300162j pubmed: 22845012

Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces. 2012;90:21–7. https://doi.org/10.1016/j.colsurfb.2011.09.042 .

doi: 10.1016/j.colsurfb.2011.09.042 pubmed: 22014934

Pandey AR, Singh US, Momin M, Bhavsar C. Chitosan: Application in tissue engineering and skin grafting. J Polym Res. 2017;24(8):125. https://doi.org/10.1007/s10965-017-1286-4 .

doi: 10.1007/s10965-017-1286-4

Rebbouh F, Martin-Eauclaire M-F, Laraba-Djebari F. Chitosan nanoparticles as a delivery platform for neurotoxin II from Androctonus australis hector scorpion venom: Assessment of toxicity and immunogenicity. Acta Trop. 2020;205:105353. https://doi.org/10.1016/j.actatropica.2020.105353 .

doi: 10.1016/j.actatropica.2020.105353 pubmed: 31982432

Zheng F, et al. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study. Life Sci. 2007;80(4):388–96. https://doi.org/10.1016/j.lfs.2006.09.040 .

doi: 10.1016/j.lfs.2006.09.040 pubmed: 17074366

El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm. 2002;249(1–2):101–8. https://doi.org/10.1016/s0378-5173(02)00461-1 .

doi: 10.1016/s0378-5173(02)00461-1 pubmed: 12433438

Xue M, et al. Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor. Int J Pharm. 2015;495(2):771–82. https://doi.org/10.1016/j.ijpharm.2015.08.056 .

doi: 10.1016/j.ijpharm.2015.08.056 pubmed: 26428629

Bagre AP, Jain K, Jain NK. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Int J Pharm. 2013;456(1):31–40. https://doi.org/10.1016/j.ijpharm.2013.08.037 .

doi: 10.1016/j.ijpharm.2013.08.037 pubmed: 23994363

Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv. 2008;5(6):703–24. https://doi.org/10.1517/17425247.5.6.703 .

doi: 10.1517/17425247.5.6.703 pubmed: 18532925

W. Yi et al., “Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry,” Signal Transduct. Target. Ther. 2022 71, vol. 7, no. 1, pp. 1–25. 2022, https://doi.org/10.1038/s41392-022-01250-1 .

J. H. Lee, D. V. Chapman, and W. M. Saltzman, “Nanoparticle Targeting with Antibodies in the Central Nervous System,” BME Front., vol. 4. 2023, https://doi.org/10.34133/BMEF.0012/ASSET/2B65EFA9-FE41-4D66-B5C9-C77E8B7E51A2/ASSETS/GRAPHIC/BMEF.0012.FIG.005.JPG .

Avti PK, Maysinger D, Kakkar A. Alkyne-azide ‘click’ chemistry in designing nanocarriers for applications in biology. Mol Basel Switz. 2013;18(8):9531–49. https://doi.org/10.3390/MOLECULES18089531 .

doi: 10.3390/MOLECULES18089531

A. Jain and K. Cheng, “The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis,” J Control Release Off J Control Release Soc., vol. 245, pp. 27–40. 2017, https://doi.org/10.1016/J.JCONREL.2016.11.016 .

M. Malatesta, “Transmission Electron Microscopy as a Powerful Tool to Investigate the Interaction of Nanoparticles with Subcellular Structures,” Int. J. Mol. Sci. 2021 Vol 22 Page 12789, vol. 22, no. 23, p. 12789, Nov. 2021, https://doi.org/10.3390/IJMS222312789 .

J. Rodriguez-Loya, M. Lerma, and J. L. Gardea-Torresdey, “Dynamic Light Scattering and Its Application to Control Nanoparticle Aggregation in Colloidal Systems: A Review,” Micromachines 2024 Vol 15 Page 24, vol. 15, no. 1, p. 24, Dec. 2023, https://doi.org/10.3390/MI15010024 .

C. H. Salamanca, A. Barrera-Ocampo, J. C. Lasso, N. Camacho, and C. J. Yarce, “Franz Diffusion Cell Approach for Pre-Formulation Characterisation of Ketoprofen Semi-Solid Dosage Forms,” Pharm. 2018 Vol 10 Page 148, vol. 10, no. 3, p. 148, Sep. 2018, https://doi.org/10.3390/PHARMACEUTICS10030148 .

Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based nanoparticles. Heliyon. 2022;8(1):e08674. https://doi.org/10.1016/j.heliyon.2021.e08674 .

doi: 10.1016/j.heliyon.2021.e08674 pubmed: 35028457

Fu Y, Kao WJ. Drug Release Kinetics and Transport Mechanisms of Non-degradable and Degradable Polymeric Delivery Systems. Expert Opin Drug Deliv. 2010;7(4):429–44. https://doi.org/10.1517/17425241003602259 .

doi: 10.1517/17425241003602259 pubmed: 20331353 pmcid: 2846103

K. Jafernik et al., “Chitosan-Based Nanoparticles as Effective Drug Delivery Systems—A review,” Molecules, vol. 28, no. 4, Art. no. 4, Jan. 2023, https://doi.org/10.3390/molecules28041963 .

Pinheiro AC, Bourbon AI, Vicente AA, Quintas MAC. Transport mechanism of macromolecules on hydrophilic bio-polymeric matrices – Diffusion of protein-based compounds from chitosan films. J Food Eng. 2013;116(3):633–8. https://doi.org/10.1016/j.jfoodeng.2012.12.038 .

doi: 10.1016/j.jfoodeng.2012.12.038

Kinsey ST, Locke BR, Dillaman RM. Molecules in motion: influences of diffusion on metabolic structure and function in skeletal muscle. J Exp Biol. 2011;214(2):263–74. https://doi.org/10.1242/jeb.047985 .

doi: 10.1242/jeb.047985 pubmed: 21177946

Hawthorne D, Pannala A, Sandeman S, Lloyd A. Sustained and targeted delivery of hydrophilic drug compounds: A review of existing and novel technologies from bench to bedside. J Drug Deliv Sci Technol. 2022;78:103936. https://doi.org/10.1016/j.jddst.2022.103936 .

doi: 10.1016/j.jddst.2022.103936

Rekik SB, Gassara S, Bouaziz J, Deratani A, Baklouti S. Enhancing hydrophilicity and permeation flux of chitosan/kaolin composite membranes by using polyethylene glycol as porogen. Appl Clay Sci. 2019;168:312–23. https://doi.org/10.1016/j.clay.2018.11.029 .

doi: 10.1016/j.clay.2018.11.029

Gonçalves VL, Laranjeira MCM, Fávere VT, Pedrosa RC. Effect of crosslinking agents on chitosan microspheres in controlled release of diclofenac sodium. Polímeros. 2005;15:6–12. https://doi.org/10.1590/S0104-14282005000100005 .

doi: 10.1590/S0104-14282005000100005

Jan MS, Alam W, Shabnam M, Jan MS, Alam W, Shabnam M. “Fundamentals Applications of Controlled Release Drug Delivery”, in Drug Development and Safety. IntechOpen. 2023. https://doi.org/10.5772/intechopen.113283 .

doi: 10.5772/intechopen.113283

Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered Nanoparticles for Drug Delivery in Cancer Therapy. Angew Chem Int Ed. 2014;53(46):12320–64. https://doi.org/10.1002/anie.201403036 .

doi: 10.1002/anie.201403036

Islam N, Dmour I, Taha MO. Degradability of chitosan micro/nanoparticles for pulmonary drug delivery. Heliyon. 2019;5(5): e01684. https://doi.org/10.1016/j.heliyon.2019.e01684 .

doi: 10.1016/j.heliyon.2019.e01684 pubmed: 31193324 pmcid: 6525292

Ren D, Yi H, Wang W, Ma X. The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. Carbohydr Res. 2005;340(15):2403–10. https://doi.org/10.1016/j.carres.2005.07.022 .

doi: 10.1016/j.carres.2005.07.022 pubmed: 16109386

Devasena T, et al. Insights on the Dynamics and Toxicity of Nanoparticles in Environmental Matrices. Bioinorg Chem Appl. 2022;2022:4348149. https://doi.org/10.1155/2022/4348149 .

doi: 10.1155/2022/4348149 pubmed: 35959228 pmcid: 9357770

Ahmadi F, Oveisi Z, Samani SM, Amoozgar Z. Chitosan based hydrogels: characteristics and pharmaceutical applications. Res Pharm Sci. 2015;10(1):1–16.

pubmed: 26430453 pmcid: 4578208

He X, Li K, Xing R, Liu S, Hu L, Li P. The production of fully deacetylated chitosan by compression method. Egypt J Aquat Res. 2016;42(1):75–81. https://doi.org/10.1016/j.ejar.2015.09.003 .

doi: 10.1016/j.ejar.2015.09.003

H. S. Mahdi and S. M. Alshrefi, “pH-Sensitive Swelling Behavior and Drug Release Kinetics of Chitosan-Modified Cs/HEMA Hydrogels,” Mar. 05, 2024. https://doi.org/10.21203/rs.3.rs-3978283/v1 .

Aranaz I, et al. Chitosan: An Overview of Its Properties and Applications. Polymers. 2021;13(19):3256. https://doi.org/10.3390/polym13193256 .

doi: 10.3390/polym13193256 pubmed: 34641071 pmcid: 8512059

Kipcak AS, Ismail O, Doymaz I, Piskin S. Modeling and Investigation of the Swelling Kinetics of Acrylamide-Sodium Acrylate Hydrogel. J Chem. 2014;2014(1):281063. https://doi.org/10.1155/2014/281063 .

doi: 10.1155/2014/281063

Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 2022;7:100048. https://doi.org/10.1016/j.onano.2022.100048 .

doi: 10.1016/j.onano.2022.100048

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–24. https://doi.org/10.1038/s41573-020-0090-8 .

doi: 10.1038/s41573-020-0090-8 pubmed: 33277608

Zuleger S, Lippold BC. Polymer particle erosion controlling drug release. I. Factors influencing drug release and characterization of the release mechanism. Int J Pharm. 2001;217(1):139–52. https://doi.org/10.1016/S0378-5173(01)00596-8 .

doi: 10.1016/S0378-5173(01)00596-8 pubmed: 11292550

Jain GK, et al. Mechanistic study of hydrolytic erosion and drug release behaviour of PLGA nanoparticles: Influence of chitosan. Polym Degrad Stab. 2010;95(12):2360–6. https://doi.org/10.1016/j.polymdegradstab.2010.08.015 .

doi: 10.1016/j.polymdegradstab.2010.08.015

Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chem Rev. 2016;116(4):2602–63. https://doi.org/10.1021/acs.chemrev.5b00346 .

doi: 10.1021/acs.chemrev.5b00346 pubmed: 26854975 pmcid: 5509216

K. Piekarska, M. Sikora, M. Owczarek, J. Jóźwik-Pruska, and M. Wiśniewska-Wrona, “Chitin and Chitosan as Polymers of the Future—Obtaining, Modification, Life Cycle Assessment and Main Directions of Application,” Polymers, vol. 15, no. 4, Art. no. 4, Jan. 2023, https://doi.org/10.3390/polym15040793 .

Sharma A, et al. Understanding the journey of biopolymeric nanoformulations for oral drug delivery: Conventional to advanced treatment approaches. Eur Polym J. 2024;218:113338. https://doi.org/10.1016/j.eurpolymj.2024.113338 .

doi: 10.1016/j.eurpolymj.2024.113338

Ioele G, et al. Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. Molecules. 2022;27(17):5436. https://doi.org/10.3390/molecules27175436 .

doi: 10.3390/molecules27175436 pubmed: 36080203 pmcid: 9457551

Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther. 2019;4:33. https://doi.org/10.1038/s41392-019-0068-3 .

doi: 10.1038/s41392-019-0068-3 pubmed: 31637012 pmcid: 6799838

L. Akhileshwar Jha et al., “Effectiveness of phytoconstituents and potential of phyto-nanomedicines combination to treat osteoarthritis,” Eur. Polym. J., vol. 215, p. 113243, Jul. 2024, https://doi.org/10.1016/j.eurpolymj.2024.113243 .

Jha LA, Kumar B, Jha SK, Paudel KR. Futuristic senolytic drug incorporated nanomedicine therapy to treat osteoarthritis. Nanomed. 2024;19(10):837–40. https://doi.org/10.2217/nnm-2023-0348 .

doi: 10.2217/nnm-2023-0348

S. K. Jha, M. Imran, S. Anwaar, P. M. Hansbro, K. R. Paudel, and Y. Mohammed, “Mesenchymal stem cell membrane-coated nanoconstructs: why have they not yet found a home in clinical practice?,” Nanomed., pp. 1–4, https://doi.org/10.1080/17435889.2024.2369495 .

Jha SK, Imran M, Paudel KR, Mohammed Y, Hansbro P, Dua K. Treating primary lymphoma of the brain in AIDS patients via multifunctional oral nanoparticulate systems. Nanomed. 2022;17(7):425–9. https://doi.org/10.2217/nnm-2021-0444 .

doi: 10.2217/nnm-2021-0444

J. Y. Chung, J. H. Ko, Y. J. Lee, H. S. Choi, and Y.-H. Kim, “Surfactant-free solubilization and systemic delivery of anti-cancer drug using low molecular weight methylcellulose,” J. Control. Release Off. J. Control. Release Soc., vol. 276, pp. 42–49, Apr. 2018, https://doi.org/10.1016/j.jconrel.2018.02.028 .

Seddiqi H, et al. Cellulose and its derivatives: towards biomedical applications. Cellulose. 2021;28(4):1893–931. https://doi.org/10.1007/s10570-020-03674-w .

doi: 10.1007/s10570-020-03674-w

P. L. Nasatto, F. Pignon, J. L. M. Silveira, M. E. R. Duarte, M. D. Noseda, and M. Rinaudo, “Methylcellulose, a Cellulose Derivative with Original Physical Properties and Extended Applications,” Polymers, vol. 7, no. 5, Art. no. 5, May 2015, https://doi.org/10.3390/polym7050777 .

Boyd BJ, et al. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019;137:104967. https://doi.org/10.1016/j.ejps.2019.104967 .

doi: 10.1016/j.ejps.2019.104967 pubmed: 31252052

A. Budiman, N. Nurfadilah, M. Muchtaridi, S. Sriwidodo, D. L. Aulifa, and A. Rusdin, “The Impact of Water-Soluble Chitosan on the Inhibition of Crystal Nucleation of Alpha-Mangostin from Supersaturated Solutions,” Polymers, vol. 14, no. 20, Art. no. 20, Jan. 2022, https://doi.org/10.3390/polym14204370 .

A. Budiman, K. Kalina, L. Aristawidya, A. A. A. Shofwan, A. Rusdin, and D. L. Aulifa, “Characterizing the Impact of Chitosan on the Nucleation and Crystal Growth of Ritonavir from Supersaturated Solutions,” Polymers, vol. 15, no. 5, Art. no. 5, Jan. 2023, https://doi.org/10.3390/polym15051282 .

W. Sadée, “Pharmacokinetics of Anticancer Drugs,” in Chemotherapy, K. Hellmann and T. A. Connors, Eds., Boston, MA: Springer US, 1976, pp. 113–117. https://doi.org/10.1007/978-1-4613-4349-3_11 .

Dewhirst MW, Secomb TW. Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer. 2017;17(12):738–50. https://doi.org/10.1038/nrc.2017.93 .

doi: 10.1038/nrc.2017.93 pubmed: 29123246 pmcid: 6371795

Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021;26(19):5905. https://doi.org/10.3390/molecules26195905 .

doi: 10.3390/molecules26195905 pubmed: 34641447 pmcid: 8512302

Levison ME, Levison JH. Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infect Dis Clin North Am. 2009;23(4):791–vii. https://doi.org/10.1016/j.idc.2009.06.008 .

doi: 10.1016/j.idc.2009.06.008 pubmed: 19909885 pmcid: 3675903

Barua S, Mitragotri S. Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today. 2014;9(2):223–43. https://doi.org/10.1016/j.nantod.2014.04.008 .

doi: 10.1016/j.nantod.2014.04.008 pubmed: 25132862 pmcid: 4129396

Behzadi S, et al. Cellular Uptake of Nanoparticles: Journey Inside the Cell. Chem Soc Rev. 2017;46(14):4218–44. https://doi.org/10.1039/c6cs00636a .

doi: 10.1039/c6cs00636a pubmed: 28585944 pmcid: 5593313

Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929–39. https://doi.org/10.1038/nrd3287 .

doi: 10.1038/nrd3287 pubmed: 21119731

Zeitlinger MA, et al. Protein Binding: Do We Ever Learn?▿. Antimicrob Agents Chemother. 2011;55(7):3067–74. https://doi.org/10.1128/AAC.01433-10 .

doi: 10.1128/AAC.01433-10 pubmed: 21537013 pmcid: 3122431

Chehelgerdi M, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22:169. https://doi.org/10.1186/s12943-023-01865-0 .

doi: 10.1186/s12943-023-01865-0 pubmed: 37814270 pmcid: 10561438

Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Controlled Release. 2010;145(3):182–95. https://doi.org/10.1016/j.jconrel.2010.01.036 .

doi: 10.1016/j.jconrel.2010.01.036

Huang M, Khor E, Lim L-Y. Uptake and Cytotoxicity of Chitosan Molecules and Nanoparticles: Effects of Molecular Weight and Degree of Deacetylation. Pharm Res. 2004;21(2):344–53. https://doi.org/10.1023/B:PHAM.0000016249.52831.a5 .

doi: 10.1023/B:PHAM.0000016249.52831.a5 pubmed: 15032318

Silva CM, Veiga F, Ribeiro AJ, Zerrouk N, Arnaud P. Effect of chitosan-coated alginate microspheres on the permeability of Caco-2 cell monolayers. Drug Dev Ind Pharm. 2006;32(9):1079–88. https://doi.org/10.1080/03639040600735020 .

doi: 10.1080/03639040600735020 pubmed: 17012120

Huang R, Mendis E, Rajapakse N, Kim S-K. Strong electronic charge as an important factor for anticancer activity of chitooligosaccharides (COS). Life Sci. 2006;78(20):2399–408. https://doi.org/10.1016/j.lfs.2005.09.039 .

doi: 10.1016/j.lfs.2005.09.039 pubmed: 16310222

Kowapradit J, et al. In vitro permeability enhancement in intestinal epithelial cells (Caco-2) monolayer of water soluble quaternary ammonium chitosan derivatives. AAPS PharmSciTech. 2010;11(2):497–508. https://doi.org/10.1208/s12249-010-9399-7 .

doi: 10.1208/s12249-010-9399-7 pubmed: 20333490 pmcid: 2902307

Loh JW, Yeoh G, Saunders M, Lim L-Y. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicol Appl Pharmacol. 2010;249(2):148–57. https://doi.org/10.1016/j.taap.2010.08.029 .

doi: 10.1016/j.taap.2010.08.029 pubmed: 20831879

El-Sherbiny IM, Smyth HDC. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol Pharm. 2012;9(2):269–80. https://doi.org/10.1021/mp200351y .

doi: 10.1021/mp200351y pubmed: 22136259

Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2012;45(5):632–8. https://doi.org/10.1016/j.ejps.2012.01.002 .

doi: 10.1016/j.ejps.2012.01.002

Grenha A, et al. Development of new chitosan/carrageenan nanoparticles for drug delivery applications. J Biomed Mater Res A. 2010;92(4):1265–72. https://doi.org/10.1002/jbm.a.32466 .

doi: 10.1002/jbm.a.32466 pubmed: 19322874

Grenha A, et al. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2007;31(2):73–84. https://doi.org/10.1016/j.ejps.2007.02.008 .

doi: 10.1016/j.ejps.2007.02.008

Lozano MV, Torrecilla D, Torres D, Vidal A, Domínguez F, Alonso MJ. Highly Efficient System To Deliver Taxanes into Tumor Cells: Docetaxel-Loaded Chitosan Oligomer Colloidal Carriers. Biomacromol. 2008;9(8):2186–93. https://doi.org/10.1021/bm800298u .

doi: 10.1021/bm800298u

Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials. 2010;31(5):908–15. https://doi.org/10.1016/j.biomaterials.2009.09.104 .

doi: 10.1016/j.biomaterials.2009.09.104 pubmed: 19853292

Chang S-Q, Kang B, Dai Y-D, Zhang H-X, Chen D. One-step fabrication of biocompatible chitosan-coated ZnS and ZnS:Mn2+ quantum dots via a γ-radiation route. Nanoscale Res Lett. 2011;6(1):591. https://doi.org/10.1186/1556-276X-6-591 .

doi: 10.1186/1556-276X-6-591 pubmed: 22082093 pmcid: 3237047

Tan WB, Zhang Y. Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications. J Biomed Mater Res A. 2005;75A(1):56–62. https://doi.org/10.1002/jbm.a.30410 .

doi: 10.1002/jbm.a.30410

Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141(5):769–76. https://doi.org/10.3945/jn.110.135657 .

doi: 10.3945/jn.110.135657 pubmed: 21430248

Johnson PH, Frank D, Costantino HR. Discovery of tight junction modulators: significance for drug development and delivery. Drug Discov Today. 2008;13(5):261–7. https://doi.org/10.1016/j.drudis.2007.10.023 .

doi: 10.1016/j.drudis.2007.10.023 pubmed: 18342803

Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev. 2006;58(1):15–28. https://doi.org/10.1016/j.addr.2006.01.003 .

doi: 10.1016/j.addr.2006.01.003 pubmed: 16517003

A. S. Pasternak and W. M. Miller, “Citation for: Measurement of trans‐epithelial electrical resistance in perfusion: Potential application for in vitro ocular toxicity testing,” Anal. Sci. J., Accessed: Jul. 30, 2024. Available: https://analyticalsciencejournals.onlinelibrary.wiley.com/action/showCitFormats?doi=10.1002%2F%28SICI%291097-0290%2819960605%2950%3A5%3C568%3A%3AAID-BIT12%3E3.0.CO%3B2-F

Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004;286(6):C1213-1228. https://doi.org/10.1152/ajpcell.00558.2003 .

doi: 10.1152/ajpcell.00558.2003 pubmed: 15151915

C. E. Stewart, E. E. Torr, N. H. Mohd Jamili, C. Bosquillon, and I. Sayers, “Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research,” J. Allergy, vol. 2012, p. 943982, 2012, https://doi.org/10.1155/2012/943982 .

Scherliess R. The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells. Int J Pharm. 2011;411(1–2):98–105. https://doi.org/10.1016/j.ijpharm.2011.03.053 .

doi: 10.1016/j.ijpharm.2011.03.053 pubmed: 21453764

Nafee N, Schneider M, Schaefer UF, Lehr C-M. Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm. 2009;381(2):130–9. https://doi.org/10.1016/j.ijpharm.2009.04.049 .

doi: 10.1016/j.ijpharm.2009.04.049 pubmed: 19450671

B. Forbes, N. Hashmi, G. P. Martin, and A. B. Lansley, “Formulation of inhaled medicines: effect of delivery vehicle on immortalized epithelial cells,” J Aerosol Med Off J Int Soc. Aerosols Med., vol. 13, no. 3, pp. 281–288, 2000, https://doi.org/10.1089/jam.2000.13.281 .

A. M. M. Sadeghi et al., “Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells,” Eur J Pharm Biopharm Off J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV, vol. 70, no. 1, pp. 270–278, Sep. 2008, https://doi.org/10.1016/j.ejpb.2008.03.004 .

Ma Z, Lim L-Y. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm Res. 2003;20(11):1812–9. https://doi.org/10.1023/b:pham.0000003379.76417.3e .

doi: 10.1023/b:pham.0000003379.76417.3e pubmed: 14661926

Loh JW, Saunders M, Lim L-Y. Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells. Toxicol Appl Pharmacol. 2012;262(3):273–82. https://doi.org/10.1016/j.taap.2012.04.037 .

doi: 10.1016/j.taap.2012.04.037 pubmed: 22609640

Mura S, et al. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine. 2011;6:2591–605. https://doi.org/10.2147/IJN.S24552 .

doi: 10.2147/IJN.S24552 pubmed: 22114491 pmcid: 3218574

Liu LX, Song CN, Song LP, Zhang HL, Dong X, Leng XG. Effects of alkylated-chitosan-DNA nanoparticles on the function of macrophages. J Mater Sci Mater Med. 2009;20(4):943–8. https://doi.org/10.1007/s10856-008-3621-0 .

doi: 10.1007/s10856-008-3621-0 pubmed: 19020960

Zhang C, et al. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials. 2008;29(9):1233–41. https://doi.org/10.1016/j.biomaterials.2007.11.029 .

doi: 10.1016/j.biomaterials.2007.11.029 pubmed: 18093646

H.-L. Jiang et al., “Chitosan-graft-spermine as a gene carrier in vitro and in vivo,” Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV, vol. 77, no. 1, pp. 36–42, Jan. 2011, https://doi.org/10.1016/j.ejpb.2010.09.014 .

Choi M, et al. Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice. Toxicol Lett. 2010;199(2):144–52. https://doi.org/10.1016/j.toxlet.2010.08.016 .

doi: 10.1016/j.toxlet.2010.08.016 pubmed: 20816729

Huang YC, Vieira A, Huang KL, Yeh MK, Chiang CH. Pulmonary inflammation caused by chitosan microparticles. J Biomed Mater Res A. 2005;75(2):283–7. https://doi.org/10.1002/jbm.a.30421 .

doi: 10.1002/jbm.a.30421 pubmed: 16059899

Pandey R, Khuller GK. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother. 2004;53(4):635–40. https://doi.org/10.1093/jac/dkh139 .

doi: 10.1093/jac/dkh139 pubmed: 14998985

Sonaje K, Lin Y-H, Juang J-H, Wey S-P, Chen C-T, Sung H-W. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials. 2009;30(12):2329–39. https://doi.org/10.1016/j.biomaterials.2008.12.066 .

doi: 10.1016/j.biomaterials.2008.12.066 pubmed: 19176244

Sonaje K, et al. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials. 2011;32(33):8712–21. https://doi.org/10.1016/j.biomaterials.2011.07.086 .

doi: 10.1016/j.biomaterials.2011.07.086 pubmed: 21862121

Kohane DS, Langer R. Biocompatibility and drug delivery systems. Chem Sci. 2010;1(4):441–6. https://doi.org/10.1039/C0SC00203H .

doi: 10.1039/C0SC00203H

Muzzarelli RA. Human enzymatic activities related to the therapeutic administration of chitin derivatives. Cell Mol Life Sci CMLS. 1997;53(2):131–40. https://doi.org/10.1007/pl00000584 .

doi: 10.1007/pl00000584 pubmed: 9118001

Nwe N, Furuike T, Tamura H. The Mechanical and Biological Properties of Chitosan Scaffolds for Tissue Regeneration Templates Are Significantly Enhanced by Chitosan from Gongronella butleri. Materials. 2009;2(2):374–98. https://doi.org/10.3390/ma2020374 .

doi: 10.3390/ma2020374 pmcid: 5445703

Bagheri-Khoulenjani S, Taghizadeh SM, Mirzadeh H. An investigation on the short-term biodegradability of chitosan with various molecular weights and degrees of deacetylation. Carbohydr Polym. 2009;78(4):773–8. https://doi.org/10.1016/j.carbpol.2009.06.020 .

doi: 10.1016/j.carbpol.2009.06.020

J. Ostrowska-Czubenko, M. Pieróg, and M. Gierszewska-Drużyńska, “Equilibrium swelling behavior of crosslinked chitosan hydrogels,” Pol. J. Appl. Chem., vol. 55, no. 2, 2011, Accessed: Aug. 06, 2024. Available: https://omega.umk.pl/info/article/UMK511713af5a314d0293b8e0e7ad963227/Publikacja+%25E2%2580%2593+Equilibrium+swelling+behavior+of+crosslinked+chitosan+hydrogels+%25E2%2580%2593+Uniwersytet+Miko%25C5%2582aja+Kopernika+w+Toruniu?r=publication&ps=20&lang=en&pn=1&cid=317431

S. Al-Qadi, A. Grenha, D. Carrión-Recio, B. Seijo, and C. Remuñán-López, “Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations,” J Control Release Off J Control Release Soc., vol. 157, no. 3, pp. 383–390, Feb. 2012, https://doi.org/10.1016/j.jconrel.2011.08.008 .

El-Sherbiny IM, Smyth HDC. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. Int J Pharm. 2010;395(1–2):132–41. https://doi.org/10.1016/j.ijpharm.2010.05.032 .

doi: 10.1016/j.ijpharm.2010.05.032 pubmed: 20580794

Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2005;25(4–5):427–37. https://doi.org/10.1016/j.ejps.2005.04.009 .

doi: 10.1016/j.ejps.2005.04.009

Poth N, Seiffart V, Gross G, Menzel H, Dempwolf W. Biodegradable Chitosan Nanoparticle Coatings on Titanium for the Delivery of BMP-2. Biomolecules. 2015;5(1):3–19. https://doi.org/10.3390/biom5010003 .

doi: 10.3390/biom5010003 pubmed: 25581889 pmcid: 4384108

Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62(1):3–11. https://doi.org/10.1016/j.addr.2009.09.004 .

doi: 10.1016/j.addr.2009.09.004 pubmed: 19800377

Cheung A, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7(32):52553–74. https://doi.org/10.18632/oncotarget.9651 .

doi: 10.18632/oncotarget.9651 pubmed: 27248175 pmcid: 5239573

Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(10):2034–43. https://doi.org/10.1093/annonc/mdv250 .

doi: 10.1093/annonc/mdv250

A. M. Fardous and A. R. Heydari, “Uncovering the Hidden Dangers and Molecular Mechanisms of Excess Folate: A Narrative Review,” Nutrients, vol. 15, no. 21, Art. no. 21, Jan. 2023, https://doi.org/10.3390/nu15214699 .

R. Zhao, N. Diop-Bove, M. Visentin, and I. D. Goldman, “Mechanisms of Membrane Transport of Folates into Cells and Across Epithelia,” Annu. Rev. Nutr., vol. 31, p.. https://doi.org/10.1146/annurev-nutr-072610-145133 , Aug. 2011, https://doi.org/10.1146/annurev-nutr-072610-145133

Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994;73(9):2432–43. https://doi.org/10.1002/1097-0142(19940501)73:9%3c2432::aid-cncr2820730929%3e3.0.co;2-s .

doi: 10.1002/1097-0142(19940501)73:9<2432::aid-cncr2820730929>3.0.co;2-s pubmed: 7513252

Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 2007;26(1):141–52. https://doi.org/10.1007/s10555-007-9048-0 .

doi: 10.1007/s10555-007-9048-0 pubmed: 17333345

Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci J Virtual Libr. 2006;11:506–19. https://doi.org/10.2741/1815 .

doi: 10.2741/1815

Bianchi E, Doe B, Goulding D, Wright GJ. Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature. 2014;508(7497):483–7.

doi: 10.1038/nature13203 pubmed: 24739963 pmcid: 3998876

O’Shannessy DJ, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3(4):414–25. https://doi.org/10.18632/oncotarget.519 .

doi: 10.18632/oncotarget.519 pubmed: 22547449 pmcid: 3380576

Shia J, et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol. 2008;39(4):498–505. https://doi.org/10.1016/j.humpath.2007.09.013 .

doi: 10.1016/j.humpath.2007.09.013 pubmed: 18342661

Tian Y, et al. A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells. BMC Immunol. 2012;13:30. https://doi.org/10.1186/1471-2172-13-30 .

doi: 10.1186/1471-2172-13-30 pubmed: 22694797 pmcid: 3724506

Kane MA, et al. Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest. 1988;81(5):1398–406. https://doi.org/10.1172/JCI113469 .

doi: 10.1172/JCI113469 pubmed: 3366900 pmcid: 442570

Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI, Canevari S. Interaction of folate receptor with signaling molecules lyn and G(alpha)(i–3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci. 2000;113(Pt 2):349–57. https://doi.org/10.1242/jcs.113.2.349 .

doi: 10.1242/jcs.113.2.349 pubmed: 10633085

Bottero F, Tomassetti A, Canevari S, Miotti S, Ménard S, Colnaghi MI. Gene Transfection and Expression of the Ovarian Carcinoma Marker Folate Binding Protein on NIH/3T3 Cells Increases Cell Growth in Vitro and in Vivo1. Cancer Res. 1993;53(23):5791–6.

pubmed: 8242637

Figini M, et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther. 2003;10(12):1018–25. https://doi.org/10.1038/sj.gt.3301962 .

doi: 10.1038/sj.gt.3301962 pubmed: 12776159

Jhaveri MS, Rait AS, Chung K-N, Trepel JB, Chang EH. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther. 2004;3(12):1505–12.

doi: 10.1158/1535-7163.1505.3.12 pubmed: 15634643

Lin J, et al. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther. 2013;14(11):1032–8. https://doi.org/10.4161/cbt.26106 .

doi: 10.4161/cbt.26106 pubmed: 24025360 pmcid: 3925658

Chen Y-L, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6(3):360–9. https://doi.org/10.1016/j.molonc.2011.11.010 .

doi: 10.1016/j.molonc.2011.11.010 pubmed: 22265591

Despierre E, et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol. 2013;130(1):192–9. https://doi.org/10.1016/j.ygyno.2013.03.024 .

doi: 10.1016/j.ygyno.2013.03.024 pubmed: 23558051

Crane LMA, et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol. 2012;35(1):9–18. https://doi.org/10.1007/s13402-011-0052-6 .

doi: 10.1007/s13402-011-0052-6

Toffoli G, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998;79(2):121–6. https://doi.org/10.1002/(sici)1097-0215(19980417)79:2%3c121::aid-ijc4%3e3.0.co;2-v .

doi: 10.1002/(sici)1097-0215(19980417)79:2<121::aid-ijc4>3.0.co;2-v pubmed: 9583724

Polley M-YC, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst. 2013;105(22):1677–83. https://doi.org/10.1093/jnci/djt282 .

doi: 10.1093/jnci/djt282 pubmed: 24136891 pmcid: 3888208

Bremer RE, Scoggin TS, Somers EB, O’Shannessy DJ, Tacha DE. Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target. Arch Pathol Lab Med. 2013;137(12):1747–52. https://doi.org/10.5858/arpa.2013-0039-OA .

doi: 10.5858/arpa.2013-0039-OA pubmed: 23570254

Hartmann LC, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007;121(5):938–42. https://doi.org/10.1002/ijc.22811 .

doi: 10.1002/ijc.22811 pubmed: 17487842

Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338(2):284–93. https://doi.org/10.1016/j.ab.2004.12.026 .

doi: 10.1016/j.ab.2004.12.026 pubmed: 15745749

Basal E, et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS ONE. 2009;4(7):e6292. https://doi.org/10.1371/journal.pone.0006292 .

doi: 10.1371/journal.pone.0006292 pubmed: 19617914 pmcid: 2707611

O’Shannessy DJ, et al. Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res. 2013;6(1):29. https://doi.org/10.1186/1757-2215-6-29 .

doi: 10.1186/1757-2215-6-29 pubmed: 23590973 pmcid: 3640997

O’Shannessy DJ, Gustavson M, Chandrasekaran LK, Dolled-Filhart M, Somers EB. Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology. Biomark Med. 2013;7(6):933–46. https://doi.org/10.2217/bmm.13.85 .

doi: 10.2217/bmm.13.85 pubmed: 24266829

Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol. 2008;15(3):889–99. https://doi.org/10.1245/s10434-007-9755-3 .

doi: 10.1245/s10434-007-9755-3 pubmed: 18181001

Nawaz FZ, Kipreos ET. Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol Metab. 2022;33(3):159–74. https://doi.org/10.1016/j.tem.2021.12.003 .

doi: 10.1016/j.tem.2021.12.003 pubmed: 35094917 pmcid: 8923831

Maharjan R, et al. Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity. Drug Deliv. 2021;28(1):2313–28. https://doi.org/10.1080/10717544.2021.1995077 .

doi: 10.1080/10717544.2021.1995077 pubmed: 34730056 pmcid: 8567874

Ali MS, Jha SK, Gupta G, Alsayari A, Wahab S, Kesharwani P. Advancements in 5-fluorouracil-Loaded liposomal nanosystems: A comprehensive review on recent innovations in nanomedicine for cancer therapy. J Drug Deliv Sci Technol. 2024;96:105730. https://doi.org/10.1016/j.jddst.2024.105730 .

doi: 10.1016/j.jddst.2024.105730

Pangeni R, et al. Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative. Int J Nanomedicine. 2019;14:6339–56. https://doi.org/10.2147/IJN.S209722 .

doi: 10.2147/IJN.S209722 pubmed: 31496690 pmcid: 6690926

R. Maharjan et al., “Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy,” Pharmaceutics, vol. 11, no. 7, Jul. 2019, https://doi.org/10.3390/PHARMACEUTICS11070332 .

C. Martín-Sabroso, A. I. Torres-Suárez, M. Alonso-González, A. Fernández-Carballido, and A. I. Fraguas-Sánchez, “Active Targeted Nanoformulations via Folate Receptors: State of the Art and Future Perspectives,” Pharm. 2022 Vol 14 Page 14, vol. 14, no. 1, p. 14, Dec. 2021, https://doi.org/10.3390/PHARMACEUTICS14010014 .

Herbert V. Absorption of Vitamin B12 and Folic Acid. Gastroenterology. 1968;54(1):110–5. https://doi.org/10.1016/S0016-5085(68)80046-0 .

doi: 10.1016/S0016-5085(68)80046-0 pubmed: 4865319

M. A. Mohammed, J. T. M. Syeda, K. M. Wasan, and E. K. Wasan, “An overview of chitosan nanoparticles and its application in non-parenteral drug delivery,” Dec. 01, 2017, MDPI AG. https://doi.org/10.3390/pharmaceutics9040053 .

P. Mura, F. Maestrelli, M. Cirri, and N. Mennini, “Multiple Roles of Chitosan in Mucosal Drug Delivery: An Updated Review,” Mar. Drugs 2022 Vol 20 Page 335, vol. 20, no. 5, p. 335, May 2022, https://doi.org/10.3390/MD20050335 .

Choukaife H, Seyam S, Alallam B, Doolaanea AA, Alfatama M. Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment. Int J Nanomedicine. 2022;17:3933–66. https://doi.org/10.2147/IJN.S375229 .

doi: 10.2147/IJN.S375229 pubmed: 36105620 pmcid: 9465052

T. Sangnim, D. Dheer, N. Jangra, K. Huanbutta, V. Puri, and A. Sharma, “Chitosan in Oral Drug Delivery Formulations: A Review,” Pharm. 2023 Vol 15 Page 2361, vol. 15, no. 9, p. 2361, Sep. 2023, https://doi.org/10.3390/PHARMACEUTICS15092361 .

Upreti M, Jyoti A, Sethi P. Tumor microenvironment and nanotherapeutics. Transl Cancer Res. 2013;2(4):309–19. https://doi.org/10.3978/j.issn.2218-676X.2013.08.11 .

doi: 10.3978/j.issn.2218-676X.2013.08.11 pubmed: 24634853

Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48(3):381–95. https://doi.org/10.1016/0163-7258(90)90056-8 .

doi: 10.1016/0163-7258(90)90056-8 pubmed: 1707544

O. Udofot, K. Affram, B. Israel, and E. Agyare, “Cytotoxicity of 5-fluorouracil-loaded pH-sensitive liposomal nanoparticles in colorectal cancer cell lines,” Integr. Cancer Sci. Ther., vol. 2, no. 5, 2015, https://doi.org/10.15761/ICST.1000150 .

Akinyelu J, Singh M, Akinyelu J, Singh M. Folate-tagged chitosan-functionalized gold nanoparticles for enhanced delivery of 5-fluorouracil to cancer cells. ApNan. 2019;9(1):7–17. https://doi.org/10.1007/S13204-018-0896-4 .

doi: 10.1007/S13204-018-0896-4

Esfandiarpour-Boroujeni S, Bagheri-Khoulenjani S, Mirzadeh H, Amanpour S. Fabrication and study of curcumin loaded nanoparticles based on folate-chitosan for breast cancer therapy application. Carbohydr Polym. 2017;168:14–21. https://doi.org/10.1016/j.carbpol.2017.03.031 .

doi: 10.1016/j.carbpol.2017.03.031 pubmed: 28457434

Cheng L, et al. Synthesis of folate-chitosan nanoparticles loaded with ligustrazine to target folate receptor positive cancer cells. Mol Med Rep. 2017;16(2):1101–8. https://doi.org/10.3892/MMR.2017.6740 .

doi: 10.3892/MMR.2017.6740 pubmed: 28627615 pmcid: 5562069

Abdipour H, Abbasi F, Nasiri M, Ghamkhari A, Ghorbani M. Multifunctional microbubbles comprising poly(lactic-co-glycolic acid), chitosan, polyethylene glycol, and folic acid for targeted cancer therapy. J Drug Deliv Sci Technol. 2024;94:105469. https://doi.org/10.1016/J.JDDST.2024.105469 .

doi: 10.1016/J.JDDST.2024.105469

D. Geethakumari, A. Bhaskaran Sathyabhama, K. Raji Sathyan, D. Mohandas, J. V. Somasekharan, and S. Thavarool Puthiyedathu, “Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines,” Int. J. Biol. Macromol., vol. 199, pp. 150–161, Feb. 2022, https://doi.org/10.1016/J.IJBIOMAC.2021.12.070 .

Yang KK, et al. Folate-modified-chitosan-coated liposomes for tumor-targeted drug delivery. J Mater Sci. 2013;48(4):1717–28. https://doi.org/10.1007/S10853-012-6930-0/METRICS .

doi: 10.1007/S10853-012-6930-0/METRICS

Rosière R, et al. New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation. Mol Pharm. 2018;15(3):899–910. https://doi.org/10.1021/ACS.MOLPHARMACEUT.7B00846 .

doi: 10.1021/ACS.MOLPHARMACEUT.7B00846 pubmed: 29341619

Wang F, Wang Y, Ma Q, Cao Y, Yu B. Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics. Artif Cells Nanomedicine Biotechnol. 2017;45(8):1530–8. https://doi.org/10.1080/21691401.2016.1260578 .

doi: 10.1080/21691401.2016.1260578

Singh RP, et al. Chitosan-folate decorated carbon nanotubes for site specific lung cancer delivery. Mater Sci Eng C. 2017;77:446–58. https://doi.org/10.1016/J.MSEC.2017.03.225 .

doi: 10.1016/J.MSEC.2017.03.225

Fathi M, Zangabad PS, Aghanejad A, Barar J, Erfan-Niya H, Omidi Y. Folate-conjugated thermosensitive O-maleoyl modified chitosan micellar nanoparticles for targeted delivery of erlotinib. Carbohydr Polym. 2017;172:130–41. https://doi.org/10.1016/J.CARBPOL.2017.05.007 .

doi: 10.1016/J.CARBPOL.2017.05.007 pubmed: 28606519

İnce İ, et al. Synthesis and characterization of folic acid-chitosan nanoparticles loaded with thymoquinone to target ovarian cancer cells. J Radioanal Nucl Chem. 2020;324(1):71–85. https://doi.org/10.1007/S10967-020-07058-Z/METRICS .

doi: 10.1007/S10967-020-07058-Z/METRICS

Dhas NL, Ige PP, Kudarha RR. Design, optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer. Powder Technol. 2015;283:234–45. https://doi.org/10.1016/J.POWTEC.2015.04.053 .

doi: 10.1016/J.POWTEC.2015.04.053

Sahu SK, Mallick SK, Santra S, Maiti TK, Ghosh SK, Pramanik P. In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery. J Mater Sci Mater Med. 2010;21(5):1587–97. https://doi.org/10.1007/S10856-010-3998-4 .

doi: 10.1007/S10856-010-3998-4 pubmed: 20111985

Pramanik A, Laha D, Pramanik P, Karmakar P. A novel drug ‘copper acetylacetonate’ loaded in folic acid-tagged chitosan nanoparticle for efficient cancer cell targeting. J Drug Target. 2014;22(1):23–33. https://doi.org/10.3109/1061186X.2013.832768 .

doi: 10.3109/1061186X.2013.832768 pubmed: 23987131

Soe ZC, et al. Folate-targeted nanostructured chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to colorectal cancer cells. Asian J Pharm Sci. 2019;14(1):40–51. https://doi.org/10.1016/J.AJPS.2018.09.004 .

doi: 10.1016/J.AJPS.2018.09.004 pubmed: 32104437

A. Ullah et al., “Biogenic Selenium Nanoparticles and Their Anticancer Effects Pertaining to Probiotic Bacteria—A Review,” Antioxidants, vol. 11, no. 10, Oct. 2022, https://doi.org/10.3390/ANTIOX11101916 .

L. M. Lazer et al., “Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles,” Colloids Surf. B Biointerfaces, vol. 217, Sep. 2022, https://doi.org/10.1016/J.COLSURFB.2022.112612 .

J. Zhou et al., “Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer,” Chin. J. Cancer Res. Chung-Kuo Yen Cheng Yen Chiu, vol. 25, no. 5, pp. 527–535, 2013, https://doi.org/10.3978/J.ISSN.1000-9604.2013.09.04 .

Khan MM, et al. Folate targeted lipid chitosan hybrid nanoparticles for enhanced anti-tumor efficacy. Nanomedicine Nanotechnol Biol Med. 2020;28:102228. https://doi.org/10.1016/j.nano.2020.102228 .

doi: 10.1016/j.nano.2020.102228

H. Song et al., “Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery,” BioMed Res. Int., vol. 2013, 2013, https://doi.org/10.1155/2013/723158 .

Salar RK, Kumar N. Synthesis and characterization of vincristine loaded folic acid–chitosan conjugated nanoparticles. Resour-Effic Technol. 2016;2(4):199–214. https://doi.org/10.1016/J.REFFIT.2016.10.006 .

doi: 10.1016/J.REFFIT.2016.10.006

Parveen S, Sahoo SK. Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma. Cancer Nanotechnol. 2010;1(1–6):47. https://doi.org/10.1007/S12645-010-0006-0 .

doi: 10.1007/S12645-010-0006-0 pubmed: 26069479 pmcid: 4452076

N. Amiryaghoubi et al., “Smart chitosan-folate hybrid magnetic nanoparticles for targeted delivery of doxorubicin to osteosarcoma cells,” Colloids Surf. B Biointerfaces, vol. 220, Dec. 2022, https://doi.org/10.1016/J.COLSURFB.2022.112911 .

Shanavas A, Sasidharan S, Bahadur D, Srivastava R. Magnetic core-shell hybrid nanoparticles for receptor targeted anti-cancer therapy and magnetic resonance imaging. J Colloid Interface Sci. 2017;486:112–20. https://doi.org/10.1016/J.JCIS.2016.09.060 .

doi: 10.1016/J.JCIS.2016.09.060 pubmed: 27697648

Sahu SK, Maiti S, Maiti TK, Ghosh SK, Pramanik P. Folate-decorated succinylchitosan nanoparticles conjugated with doxorubicin for targeted drug delivery. Macromol Biosci. 2011;11(2):285–95. https://doi.org/10.1002/MABI.201000353 .

doi: 10.1002/MABI.201000353 pubmed: 21104879

Ji XX, Song XL, Qian W, Yu XL, Zhu JY. Effects and mechanism of action of ligustrazine on isoprenaline-induced cardiomyocyte hypertrophy. Cell Biochem Biophys. 2014;70(3):1513–8. https://doi.org/10.1007/S12013-014-0086-2 .

doi: 10.1007/S12013-014-0086-2 pubmed: 25027096

H. X. Li, J. H. Tian, H. Y. Li, X. Wan, and Y. Zou, “Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents,” Molecules, vol. 28, no. 8, Apr. 2023, https://doi.org/10.3390/MOLECULES28083355/S1 .

Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol. 2013;71(5):1115–30. https://doi.org/10.1007/S00280-012-2062-0 .

doi: 10.1007/S00280-012-2062-0 pubmed: 23292116

Massadeh S, Alaamery M, Al-Qatanani S, Alarifi S, Bawazeer S, Alyafee Y. Synthesis of protein-coated biocompatible methotrexate-loaded PLA-PEG-PLA nanoparticles for breast cancer treatment. Nano Rev Exp. 2016;7(1):31996. https://doi.org/10.3402/NANO.V7.31996 .

doi: 10.3402/NANO.V7.31996 pmcid: 4919641

Ali EMM, Elashkar AA, El-Kassas HY, Salim EI. Methotrexate loaded on magnetite iron nanoparticles coated with chitosan: Biosynthesis, characterization, and impact on human breast cancer MCF-7 cell line. Int J Biol Macromol. 2018;120(Pt A):1170–80. https://doi.org/10.1016/J.IJBIOMAC.2018.08.118 .

doi: 10.1016/J.IJBIOMAC.2018.08.118 pubmed: 30172815

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654 .

doi: 10.3322/caac.21654 pubmed: 33433946

Muthu MS, Kutty RV, Luo Z, Xie J, Feng S-S. Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters. Biomaterials. 2015;39:234–48. https://doi.org/10.1016/j.biomaterials.2014.11.008 .

doi: 10.1016/j.biomaterials.2014.11.008 pubmed: 25468374

Niu S, et al. l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells. Drug Deliv. 2018;25(1):1275–88. https://doi.org/10.1080/10717544.2018.1477863 .

doi: 10.1080/10717544.2018.1477863 pubmed: 29847177 pmcid: 6060704

Fathi M, Barar J, Erfan-Niya H, Omidi Y. Methotrexate-conjugated chitosan-grafted pH- and thermo-responsive magnetic nanoparticles for targeted therapy of ovarian cancer. Int J Biol Macromol. 2020;154:1175–84. https://doi.org/10.1016/J.IJBIOMAC.2019.10.272 .

doi: 10.1016/J.IJBIOMAC.2019.10.272 pubmed: 31730949

Rinaudo M, Le Dung P, Gey C, Milas M. Substituent distribution on O, N-carboxymethylchitosans by 1H and 13C n.m.r. Int J Biol Macromol. 1992;14(3):122–8. https://doi.org/10.1016/S0141-8130(05)80001-7 .

doi: 10.1016/S0141-8130(05)80001-7 pubmed: 1390443

Guo Y, Zhang J, Yang L, Wang H, Wang F, Zheng Z. Syntheses of amorphous and crystalline cupric sulfide nanoparticles and study on the specific activities on different cells. Chem Commun. 2010;46(20):3493–5. https://doi.org/10.1039/C001714K .

doi: 10.1039/C001714K

Choi YH, Han HK. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig. 2018;48(1):43. https://doi.org/10.1007/S40005-017-0370-4 .

doi: 10.1007/S40005-017-0370-4 pubmed: 30546919

Hoang NH, et al. A nano-sized blending system comprising identical triblock copolymers with different hydrophobicity for fabrication of an anticancer drug nanovehicle with high stability and solubilizing capacity. Int J Nanomedicine. 2019;14:3629. https://doi.org/10.2147/IJN.S191126 .

doi: 10.2147/IJN.S191126 pubmed: 31190816 pmcid: 6530556

C. Senthil Kumar, R. Thangam, S. A. Mary, P. R. Kannan, G. Arun, and B. Madhan, “Targeted delivery and apoptosis induction of trans-resveratrol-ferulic acid loaded chitosan coated folic acid conjugate solid lipid nanoparticles in colon cancer cells,” Carbohydr. Polym., vol. 231, Mar. 2020, https://doi.org/10.1016/J.CARBPOL.2019.115682 .

Ullah S, et al. 5-Fluorouracil-Loaded Folic-Acid-Fabricated Chitosan Nanoparticles for Site-Targeted Drug Delivery Cargo. Polymers. 2022;14(10):2010. https://doi.org/10.3390/polym14102010 .

doi: 10.3390/polym14102010 pubmed: 35631891 pmcid: 9145180

Xu B, Zheng WY, Jin DY, Wang DS, Liu XY, Qin XY. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene. Cancer. 2012;118(21):5217–26. https://doi.org/10.1002/CNCR.27535 .

doi: 10.1002/CNCR.27535 pubmed: 22517373

Leamon CP, et al. Folate–Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship. Bioconjug Chem. 2014;25(3):560–8. https://doi.org/10.1021/bc400441s .

doi: 10.1021/bc400441s pubmed: 24564229

Bartouskova M, Melichar B, Mohelnikova-Duchonova B. Folate receptor: a potential target in ovarian cancer. Pteridines. 2015;26(1):1–12. https://doi.org/10.1515/pterid-2014-0013 .

doi: 10.1515/pterid-2014-0013

Banerjee S, et al. A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2022;28(21):4634–41. https://doi.org/10.1158/1078-0432.CCR-22-1268 .

doi: 10.1158/1078-0432.CCR-22-1268 pubmed: 35984704 pmcid: 9623233

Seitz JD, Vineberg JG, Herlihy E, Park B, Melief E, Ojima I. Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate. Bioorg Med Chem. 2015;23(9):2187–94. https://doi.org/10.1016/j.bmc.2015.02.057 .

doi: 10.1016/j.bmc.2015.02.057 pubmed: 25819334 pmcid: 4398638

Alsarraf J, et al. A dendritic β-galactosidase-responsive folate–monomethylauristatin E conjugate. Chem Commun. 2015;51(87):15792–5. https://doi.org/10.1039/C5CC05294G .

doi: 10.1039/C5CC05294G

Santos FMF, et al. Modular Assembly of Reversible Multivalent Cancer-Cell-Targeting Drug Conjugates. Angew Chem Int Ed Engl. 2017;56(32):9346–50. https://doi.org/10.1002/anie.201703492 .

doi: 10.1002/anie.201703492 pubmed: 28594469

Ke M-R, Yeung S-L, Ng DKP, Fong W-P, Lo P-C. Preparation and in Vitro Photodynamic Activities of Folate-Conjugated Distyryl Boron Dipyrromethene Based Photosensitizers. J Med Chem. 2013;56(21):8475–83. https://doi.org/10.1021/jm4009168 .

doi: 10.1021/jm4009168 pubmed: 24088087

C. Kurkjian et al., “A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.,” J. Clin. Oncol., vol. 31, no. 15_suppl, pp. 2573–2573, May 2013, https://doi.org/10.1200/jco.2013.31.15_suppl.2573 .

K. N. Moore et al., “Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.,” J. Clin. Oncol., vol. 32, no. 15_suppl, pp. 5571–5571, May 2014, https://doi.org/10.1200/jco.2014.32.15_suppl.5571 .

Feng Y, et al. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res Ther. 2011;13(2):R59. https://doi.org/10.1186/ar3312 .

doi: 10.1186/ar3312 pubmed: 21477314 pmcid: 3132054

R. M. Schultz, “Preclinical development of Alimta

Patel NR, et al. Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer. Mol Pharm. 2016;13(6):1996–2009. https://doi.org/10.1021/acs.molpharmaceut.6b00149 .

doi: 10.1021/acs.molpharmaceut.6b00149 pubmed: 27170232

Wang Y, et al. Synthesis, characterization and in vitro anticancer activity of the biomolecule-based coordination complex nanotubes. J Mater Chem B. 2015;3(2):296–305. https://doi.org/10.1039/C4TB01135J .

doi: 10.1039/C4TB01135J pubmed: 32261950

Lu Y, et al. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm. 2007;4(5):707–12. https://doi.org/10.1021/mp070058l .

doi: 10.1021/mp070058l pubmed: 17708654

Samiraninezhad N, Rezaee M, Gholami A, Amanati A, Mardani M. A novel chitosan-based doxepin nano-formulation for chemotherapy-induced oral mucositis: a randomized, double-blinded, placebo-controlled clinical trial. Inflammopharmacology. 2023;31(5):2411–20. https://doi.org/10.1007/s10787-023-01325-7 .

doi: 10.1007/s10787-023-01325-7 pubmed: 37668810

El-Kamary SS, et al. Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody-Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues. J Infect Dis. 2010;202(11):1649–58. https://doi.org/10.1086/657087 .

doi: 10.1086/657087 pubmed: 20979455 pmcid: 3722871

Mills KHG, et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun. 2003;71(2):726–32. https://doi.org/10.1128/IAI.71.2.726-732.2003 .

doi: 10.1128/IAI.71.2.726-732.2003 pubmed: 12540551 pmcid: 145378

Muthu MS, Wilson B. Challenges Posed by The Scale-Up of Nanomedicines. Nanomed. 2012;7(3):307–9. https://doi.org/10.2217/nnm.12.3 .

doi: 10.2217/nnm.12.3

Desai N. Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J. 2012;14(2):282–95. https://doi.org/10.1208/s12248-012-9339-4 .

doi: 10.1208/s12248-012-9339-4 pubmed: 22407288 pmcid: 3326161

Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63(6):456–69. https://doi.org/10.1016/j.addr.2011.02.001 .

doi: 10.1016/j.addr.2011.02.001 pubmed: 21315781

Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomed. 2016;11(6):673–92. https://doi.org/10.2217/nnm.16.5 .

doi: 10.2217/nnm.16.5

Chen W, Palazzo A, Hennink WE, Kok RJ. Effect of Particle Size on Drug Loading and Release Kinetics of Gefitinib-Loaded PLGA Microspheres. Mol Pharm. 2017;14(2):459–67. https://doi.org/10.1021/acs.molpharmaceut.6b00896 .

doi: 10.1021/acs.molpharmaceut.6b00896 pubmed: 27973854

Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Prashant Kesharwani (P)

Kratika Halwai (K)

Saurav Kumar Jha (SK)

Mohammed H Al Mughram (MH)

Salem Salman Almujri (SS)

Waleed H Almalki (WH)

Amirhossein Sahebkar (A)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH